OverviewSuggest Edit

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company's primary focus is on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy drug candidates.

TypePublic
Founded1980
HQCambridge, MA, US
Websitesarepta.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)743(+49%)
Job Openings79
Revenue (FY, 2020)$540.1 M(+42%)
Share Price (Jul 2021)$67.8(-1%)

Key People/Management at Sarepta Therapeutics

Douglas S. Ingram

Douglas S. Ingram

President, Chief Executive Officer & Director
Diane Berry

Diane Berry

Senior Vice President, Global Health Policy and Government and Patient Affairs
Ian M. Estepan

Ian M. Estepan

Senior Vice President, Chief of Staff and Corporate Affairs
Gilmore O'Neill

Gilmore O'Neill

Executive Vice President, R&D and Chief Medical Officer
Louise Rodino-Klapac

Louise Rodino-Klapac

Executive Vice President, Chief Scientific Officer
Joan Nickerson

Joan Nickerson

Senior Vice President, Human Resources
Show more

Sarepta Therapeutics Office Locations

Sarepta Therapeutics has offices in Cambridge, Canton, Providence, Boulogne-Billancourt and in 7 other locations
Cambridge, MA, US (HQ)
215 First St
Canton, MA, US
250 Royall St
Boulogne-Billancourt, FR
90 Route de la Reine
Berlin, DE
Friedrichstraße 88
Dublin, IE
Regus House, Harcourt Centre, Saint Kevin's
Milano, IT
Piazzale Biancamano, 8
Show all (12)

Sarepta Therapeutics Financials and Metrics

Sarepta Therapeutics Revenue

Sarepta Therapeutics's revenue was reported to be $540.1 m in FY, 2020
USD

Revenue (Q1, 2021)

146.9m

Net income (Q1, 2021)

(167.2m)

EBIT (Q1, 2021)

(151.9m)

Market capitalization (30-Jul-2021)

5.4b

Closing stock price (30-Jul-2021)

67.8

Cash (31-Mar-2021)

1.5b

EV

4.2b
Sarepta Therapeutics's current market capitalization is $5.4 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

37.3m14.2m9.8m1.3m5.4m154.6m301.0m380.8m540.1m

Revenue growth, %

(31%)(87%)333%

Cost of goods sold

130.0k

Gross profit

5.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

4.5m3.0m4.2m6.1m2.6m1.1m16.3m35.0m46.0m64.6m73.5m78.5m87.0m94.7m99.0m113.7m137.4m143.9m146.9m

Cost of goods sold

252.0k534.0k

Gross profit

16.1m34.5m

Gross profit Margin, %

98%98%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

39.9m187.7m257.0m73.6m80.3m122.4m599.7m370.8m835.1m1.5b

Accounts Receivable

3.6m4.7m3.5m2.4m4.0m5.2m29.5m49.0m90.9m101.3m

Prepaid Expenses

1.6m1.5m3.1m35.0m17.4m36.5m77.8m81.9m

Inventories

12.8m83.6m125.4m171.4m232.0m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.3m)(121.3m)(112.0m)(135.8m)(220.0m)(267.3m)(50.7m)(361.9m)(715.1m)(554.1m)

Depreciation and Amortization

1.3m1.5m1.3m3.7m5.2m5.6m8.1m12.2m30.5m26.9m

Inventories

(12.8m)(70.8m)(41.8m)(45.9m)(60.6m)

Accounts Payable

9.5m10.8m
USDQ2, 2011

Financial Leverage

2.1 x
Show all financial metrics

Sarepta Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Sarepta Therapeutics Online and Social Media Presence

Embed Graph

Sarepta Therapeutics News and Updates

Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021

CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021. Subsequently, at 4:30 p.m.…

Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Tuesday, May 18, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 12-week exp…

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of the MOMENTUM study (Study 5051-201), a global, Phase 2, multi-ascending dose clinical trial of SR…

Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequently, at 4:30 p.m. E.…

Outlook on the Antisense Oligonucleotide Therapeutics Global Market to 2030 - Featuring Biogen, Bio-Path Holdings and Sarepta Therapeutics Among Others

Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Should You Buy Sarepta Therapeutics Stock For 50% Gains?

We believe that ​Sarepta Therapeutics stock, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying opportunity at the present time. SRPT stock trades near $83 currently and it is, in fact...
Show more

Sarepta Therapeutics Blogs

Sarepta Therapeutics Second Quarter 2021 Earnings Call

Sarepta Therapeutics Second Quarter 2021 Earnings Call Katherine.Howe… Wed, 07/28/2021 - 08:47 Sarepta Therapeutics Second Quarter 2021 Earnings Call Display "add to calendar" true Event Type Earnings Conference Call Event Cate…

Sarepta Therapeutics at the Goldman Sachs 42nd Annual Global Healthcare Conference

Sarepta Therapeutics at the Goldman Sachs 42nd Annual Global Healthcare Conference Katherine.Howe… Fri, 06/04/2021 - 08:32 Sarepta Therapeutics at the Goldman Sachs 42nd Annual Global Healthcare Conference Display "add to calendar" true Event Type …

Sarepta Therapeutics at the BofA Securities 2021 Napa BioPharma Virtual Conference

Sarepta Therapeutics at the BofA Securities 2021 Napa BioPharma Virtual Conference Katherine.Howe… Fri, 06/04/2021 - 08:30 Sarepta Therapeutics at the BofA Securities 2021 Napa BioPharma Virtual Conference Display "add to calendar" true Event Type …

Clinical Update: Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material

Clinical Update: Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material Katherine.Howe… Thu, 05/06/2021 - 21:26 Clinical Update: Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material Display "add to calenda…

Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments Content Import Wed, 05/05/2021 - 16:06 Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments 05/05/21 4:05 PM EDT This relea…

Sarepta Therapeutics at the RBC 2021 Global Healthcare Conference

Sarepta Therapeutics at the RBC 2021 Global Healthcare Conference Katherine.Howe… Wed, 05/05/2021 - 06:54 Sarepta Therapeutics at the RBC 2021 Global Healthcare Conference Display "add to calendar" true Event Type Other Corporate …
Show more

Sarepta Therapeutics Frequently Asked Questions

  • When was Sarepta Therapeutics founded?

    Sarepta Therapeutics was founded in 1980.

  • Who are Sarepta Therapeutics key executives?

    Sarepta Therapeutics's key executives are Douglas S. Ingram, Diane Berry and Ian M. Estepan.

  • How many employees does Sarepta Therapeutics have?

    Sarepta Therapeutics has 743 employees.

  • What is Sarepta Therapeutics revenue?

    Latest Sarepta Therapeutics annual revenue is $540.1 m.

  • What is Sarepta Therapeutics revenue per employee?

    Latest Sarepta Therapeutics revenue per employee is $726.9 k.

  • Who are Sarepta Therapeutics competitors?

    Competitors of Sarepta Therapeutics include Ionis Pharmaceuticals, Moderna and Intarcia Therapeutics.

  • Where is Sarepta Therapeutics headquarters?

    Sarepta Therapeutics headquarters is located at 215 First St, Cambridge.

  • Where are Sarepta Therapeutics offices?

    Sarepta Therapeutics has offices in Cambridge, Canton, Providence, Boulogne-Billancourt and in 7 other locations.

  • How many offices does Sarepta Therapeutics have?

    Sarepta Therapeutics has 12 offices.